Related Experiment Video
Updated: Oct 10, 2025
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
TPGS2000-DOX Prodrug Micelles for Improving Breast Cancer Therapy
Lan Tang1, Wenhui Jiang1, Lan Wu1
1College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, People's Republic of China.
Background:
Doxorubicin (DOX) is an anthracycline antibiotic that inhibits the growth of several solid and hematologic malignant tumors. Increasing the targeting ability of DOX and reducing the multi-drug resistance (MDR) of tumor cells to DOX are major aims for researchers.
Purpose:
In this study, to increase therapeutic efficiency, reduce the side effects and the MDR of tumor cells to DOX, D-alpha-tocopheryl polyethylene glycol 2000 succinate monoester (TPGS2000)-DOX prodrug micelles were developed by grafting DOX to TPGS2000 via an amide bond that release DOX in the slightly acidic conditions in tumor tissue.
Materials And Methods:
The TPGS2000-DOX micelles were constructed using polyethylene glycol 12-hydroxy stearate (Solutol HS15) as the carrier. The in vitro drug release profile and dilution stability of the nanomicelles were determined. The in vitro cytotoxicity and distribution of the nanomicelles in the tumor cells were also investigated. Moreover, we explored the therapeutic outcomes using the MCF-7/ADR tumor-bearing murine model.
Results:
The average particle size was approximately 30 nm with a narrow distribution, which was conducive for solid tumor accumulation. The results of in vivo imaging and in vitro cellular uptake assays demonstrated that the TPGS2000-DOX micelles increased the tumor-targeting ability and cellular uptake of DOX. The anticancer potential of TPGS2000-DOX micelles was higher than that of DOX, as revealed by in vitro cytotoxic assays with MCF-7/ADR cells and in vivo antitumor assays with MCF-7 tumor-bearing nude mice.
Conclusion:
TPGS2000-DOX prodrug micelles reverse the MDR of tumor cells, achieve passive targeting by forming nanomicelles, and subsequently enhance the efficacy and reduce the toxicity of DOX.
Insights
D-alpha-tocopheryl polyethylene glycol 2000 succinate monoester (TPGS2000)-doxorubicin (DOX) prodrug micelles enhance DOX tumor targeting and efficacy. These nanomicelles reduce multi-drug resistance (MDR) and toxicity, improving cancer treatment outcomes.
Area of Science:
- Nanomedicine
- Drug Delivery Systems
- Cancer Therapeutics
Background:
- Doxorubicin (DOX) is a key chemotherapy agent against various cancers.
- Increasing DOX tumor targeting and overcoming multi-drug resistance (MDR) are critical research goals.
Purpose of the Study:
- Develop TPGS2000-DOX prodrug micelles to enhance DOX therapeutic efficiency.
- Reduce DOX side effects and overcome tumor cell MDR.
- Achieve pH-sensitive DOX release in tumor tissues.
Main Methods:
- Constructed TPGS2000-DOX micelles using Solutol HS15 as a carrier.
- Evaluated in vitro drug release, stability, cytotoxicity, and cellular uptake.
- Assessed therapeutic outcomes in a murine MCF-7/ADR tumor model.
Main Results:
- Formed stable nanomicelles (approx. 30 nm) for tumor accumulation.
- Demonstrated enhanced tumor targeting and cellular uptake of DOX.
- Showcased superior in vitro and in vivo anticancer efficacy compared to free DOX.
Conclusions:
- TPGS2000-DOX prodrug micelles effectively reverse MDR in tumor cells.
- Nanomicelle formation facilitates passive tumor targeting.
- The developed micelles enhance DOX efficacy while reducing toxicity.
